Oncology NEWS International April 2009 Vol. 18 No. 4


Cover Story

Optimal use of aromatase inhibitors comes into focus

Masters of hematology and oncology: David Alberts, MD


News & Analysis

Pharmaceutical mergers raise fears of treatment pipeline pruning

Prophylaxis fends off life-threatening invasive fungal infections

MR spectroscopy separates brain tumor recurrence from radiation necrosis

Medicare approves coverage of FDG-PET scans for 11 cancers

Cancer Care: Practice & Policy

Two major studies add fuel to fire of PSA controversy

Focus on Prostate Cancer

Evidence grows for value of high-field MRI in prostate cancer Rx

Most prognostic prostate cancer markers lack clinical utility

Focus on Colon Cancer

Minority groups protest CMS rejection of CT-based colon cancer screening

Focus on Hematology

Clear-cut evidence for routine use of ESA agents remains elusive

Related Videos
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Related Content